Synlogic is powering the microbiome with a new class of medicines called “synthetic biotics™.”
At Synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome.
Using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors.
We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic bioticsTM to address more prevalent conditions, including inflammatory bowel disease (IBD), cancer and metabolic conditions such as diabetes and obesity.
Synlogic is led by industry veterans who have pioneered new therapeutic approaches, commercialized drugs and built companies. We are fortunate to be backed by leading life sciences investors, including Atlas Venture, New Enterprise Associates (NEA), the Bill & Melinda Gates Foundation, Orbimed and Deerfield Management.